Alpha 2.0
Login Register
» Authors » Michael Vogelbaum

Michael Vogelbaum

Explore the profile of Michael Vogelbaum including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 1511
Followers 0
Related Specialties
Oncology
Neurology
Radiology
Top 10 Co-Authors
Susan Chang
Michael Weller
Patrick Y Wen
Martin J van den Bent
Norbert Galldiks
Evanthia Galanis
David A Reardon
Raymond Y Huang
David Schiff
Gene Barnett
Published In
Neuro Oncol
Lancet Oncol
J Neurooncol
J Neurosci
Proc Natl Acad Sci U S A
Affiliations
Soon will be listed here.
Recent Articles
1.
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice
Bakas S, Vollmuth P, Galldiks N, Booth T, Aerts H, Bi W, et al.
Lancet Oncol . 2024 Oct; 25(11):e589-e601. PMID: 39481415
Technological advancements have enabled the extended investigation, development, and application of computational approaches in various domains, including health care. A burgeoning number of diagnostic, predictive, prognostic, and monitoring biomarkers are...
2.
Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0
Albert N, Preusser M, Traub-Weidinger T, Tolboom N, Law I, Palmer J, et al.
Eur J Nucl Med Mol Imaging . 2024 Jun; 51(12):3662-3679. PMID: 38898354
Purpose: To provide practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands. Methods: This joint practice guideline/procedure standard was collaboratively developed by the...
3.
The impact of opioid administration for post gamma knife radiosurgery frame removal: a prospective quality-improvement study
Hsieh J, Wei W, Nie J, Barnett G, Mohammadi A, Stevens G, et al.
J Neurooncol . 2023 Sep; 164(3):721-728. PMID: 37749305
Purpose: In our center, five Gamma Knife proceduralists differed in opioid administration practices prior to Leksell frame removal, providing the opportunity to improve the care of patients with brain metastases...
4.
Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial
Sampson J, Singh Achrol A, Aghi M, Bankiewicz K, Bexon M, Brem S, et al.
Neuro Oncol . 2023 Jan; 25(6):1085-1097. PMID: 36640127
Background: MDNA55 is an interleukin 4 receptor (IL4R)-targeting toxin in development for recurrent GBM, a universally fatal disease. IL4R is overexpressed in GBM as well as cells of the tumor...
5.
A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma
Law V, Chen Z, Vena F, Smalley I, MacAulay R, Evernden B, et al.
Neuro Oncol . 2022 Feb; 24(10):1673-1686. PMID: 35213727
Background: Leptomeningeal disease (LMD) occurs as a late complication of several human cancers and has no rationally designed treatment options. A major barrier to developing effective therapies for LMD is...
6.
Long-term trends in glioblastoma survival: implications for historical control groups in clinical trials
Sheikh S, Radivoyevitch T, Barnholtz-Sloan J, Vogelbaum M
Neurooncol Pract . 2020 Jul; 7(2):158-163. PMID: 32626584
Background: Historical controls continue to be used in early-phase brain tumor trials. We aim to show that historical changes in survival trends for glioblastoma (GBM) call into question the use...
7.
Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group
Huang R, Bi W, Weller M, Kaley T, Blakeley J, Dunn I, et al.
Neuro Oncol . 2018 Aug; 21(1):26-36. PMID: 30137421
No standard criteria exist for assessing response and progression in clinical trials involving patients with meningioma, and there is no consensus on the optimal endpoints for trials currently under way....
8.
Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma
Sharma M, Bellamkonda S, Mohapatra S, Meola A, Jia X, Mohammadi A, et al.
World Neurosurg . 2018 May; 116:e147-e161. PMID: 29709748
Background: There is limited information on O-methylguanine DNA methyltransferase (MGMT) status, extent of surgical resection, and its impact on overall outcomes in patients with glioblastoma (GBM). Methods: After institutional review...
9.
Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline
Cabrera A, Kirkpatrick J, Fiveash J, Shih H, Koay E, Lutz S, et al.
Pract Radiat Oncol . 2016 May; 6(4):217-225. PMID: 27211230
Purpose: To present evidence-based guidelines for radiation therapy in treating glioblastoma not arising from the brainstem. Methods And Materials: The American Society for Radiation Oncology (ASTRO) convened the Glioblastoma Guideline...
10.
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
Albert N, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim M, et al.
Neuro Oncol . 2016 Apr; 18(9):1199-208. PMID: 27106405
This guideline provides recommendations for the use of PET imaging in gliomas. The review examines established clinical benefit in glioma patients of PET using glucose ((18)F-FDG) and amino acid tracers...